HAMILTON CHRISTINE E

SEC source: 0001628280-26-041863 · wk-form4_1781031539.xml · nonDerivative · entry 1

HAMILTON CHRISTINE E · CIK 0001216114 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,498

SEC source: 0001409171-25-000060 · wk-form4_1748975342.xml · nonDerivative · entry 1

HAMILTON CHRISTINE E · CIK 0001216114 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,145

SEC source: 0000950170-24-084290 · ownership.xml · derivative · entry 5

HAMILTON CHRISTINE E · CIK 0001216114 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse.

Disclosed balance after: 2,326

Underlying: Common Stock · 2,326 shares

Expires 2034-07-15

F5 · security: Represents a one-time grant to the Reporting Person's spouse as an advisor to the Board. Shares underlying the option vest in three equal annual installments on July 15, 2025, 2026, and 2027.

F6 · security: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

F5 · derivative.exercise_date: Represents a one-time grant to the Reporting Person's spouse as an advisor to the Board. Shares underlying the option vest in three equal annual installments on July 15, 2025, 2026, and 2027.

SEC source: 0000950170-24-084290 · ownership.xml · derivative · entry 4

HAMILTON CHRISTINE E · CIK 0001216114 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse.

Disclosed balance after: 44,202

Underlying: Common Stock · 44,202 shares

Expires 2024-07-15

F4 · security: Represents a one-time grant to the Reporting Person's spouse as an advisor to the Board. Shares underlying the option are fully vested.

F6 · security: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

F4 · derivative.exercise_date: Represents a one-time grant to the Reporting Person's spouse as an advisor to the Board. Shares underlying the option are fully vested.

SEC source: 0000950170-24-084290 · ownership.xml · derivative · entry 3

HAMILTON CHRISTINE E · CIK 0001216114 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,447

Underlying: Common Stock · 4,447 shares

Expires 2034-07-15

F3 · security: Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on July 15, 2025, 2026, and 2027.

F6 · security: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

F3 · derivative.exercise_date: Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option vest in three equal annual installments on July 15, 2025, 2026, and 2027.

SEC source: 0000950170-24-084290 · ownership.xml · derivative · entry 2

HAMILTON CHRISTINE E · CIK 0001216114 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,815

Underlying: Common Stock · 5,815 shares

Expires 2034-07-15

F2 · security: Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option are fully vested.

F6 · security: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

F2 · derivative.exercise_date: Represents a one-time grant to the Reporting Person as a member of the Board. Shares underlying the option are fully vested.

SEC source: 0000950170-24-084290 · ownership.xml · derivative · entry 1

HAMILTON CHRISTINE E · CIK 0001216114 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2034-07-15

F1 · security: Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the "Board"). Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026.

F6 · security: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

F1 · derivative.exercise_date: Represents the 2024 annual grant to the Reporting Person as a member of the Board of Directors of the Issuer (the "Board"). Shares underlying the option vest in two equal annual installments on July 15, 2025, and 2026.

SEC source: 0001409171-24-000077 · wk-form4_1717598648.xml · nonDerivative · entry 1

HAMILTON CHRISTINE E · CIK 0001216114 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,823

SEC source: 0001409171-23-000058 · wk-form4_1686064210.xml · nonDerivative · entry 1

HAMILTON CHRISTINE E · CIK 0001216114 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,427

SEC source: 0001209191-22-060501 · doc4.xml · derivative · entry 3

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 82,987

Underlying: Common Stock · 82,987 shares

Expires 2027-12-07

F1 · price: On December 6, 2022, the Registrant entered into a securities purchase agreement with Ms. Christine Hamilton and Dr. Edward Hamilton in connection with a private placement conducted by the Registrant, pursuant to which Ms. Hamilton and Dr. Hamilton purchased (i) an aggregate of 82,987 shares (the "Shares") of the Registrant's common stock, par value $0.0001 per share and (ii) warrants to purchase up to an aggregate of 82,987 shares of common stock at an exercise price of $1.08, at a combined purchase price of $1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance.

SEC source: 0001209191-22-060501 · doc4.xml · nonDerivative · entry 1

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 3,111,334

F1 · date: On December 6, 2022, the Registrant entered into a securities purchase agreement with Ms. Christine Hamilton and Dr. Edward Hamilton in connection with a private placement conducted by the Registrant, pursuant to which Ms. Hamilton and Dr. Hamilton purchased (i) an aggregate of 82,987 shares (the "Shares") of the Registrant's common stock, par value $0.0001 per share and (ii) warrants to purchase up to an aggregate of 82,987 shares of common stock at an exercise price of $1.08, at a combined purchase price of $1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance.

F1 · price: On December 6, 2022, the Registrant entered into a securities purchase agreement with Ms. Christine Hamilton and Dr. Edward Hamilton in connection with a private placement conducted by the Registrant, pursuant to which Ms. Hamilton and Dr. Hamilton purchased (i) an aggregate of 82,987 shares (the "Shares") of the Registrant's common stock, par value $0.0001 per share and (ii) warrants to purchase up to an aggregate of 82,987 shares of common stock at an exercise price of $1.08, at a combined purchase price of $1.205 per share and accompanying warrant. The warrants are exercisable six months from the date of issuance and expire five years from the date of issuance.

F2 · balance_after: Reflects dispositions of 2,000,000 shares of common stock by Ms. Hamilton's spouse for bona fide estate planning purposes exempt from the report requirements of Section 16 under the Securities Exchange Act of 1934, as amended.

SEC source: 0001209191-22-049950 · doc4.xml · nonDerivative · entry 1

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,993,090

F1 · balance_after: Does not include: (i) 25,000 shares of common stock held by Christensen Investments, LLC, (ii) 2,909,022 shares of common stock held by the reporting persons spouse, Dr. Edward Hamilton, and (iii) 91,261 shares of common stock which the reporting person co-owns with Dr. Hamilton, all of which the reporting person may be deemed to beneficially own. The reporting person disclaims any beneficial ownership of these shares of common stock other than to the extent of any pecuniary interests the reporting person may have therein.

SEC source: 0001437749-23-003040 · rdgdoc.xml · nonDerivative · entry 1

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse.

Disclosed balance after: 3,083,270

F1 · price: Represents a bona fide gift of common stock for no consideration.

SEC source: 0001409171-22-000059 · wf-form4_165464163816997.xml · nonDerivative · entry 1

HAMILTON CHRISTINE E · CIK 0001216114 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,438

SEC source: 0001493152-21-026382 · ownership.xml · derivative · entry 21

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 187,975

Underlying: Common Stock · 187,975 shares

Expires not disclosed

F10 · derivative.exercise_price: In connection with the business combination, the reporting person received additional New SAB Biotherapeutics restricted stock units, or RSUs, where each RSU represents a contingent right to receive one share of common stock (the "Earnout RSUs"). The Earnout RSUs will be released upon the same milestones as the Earnout Shares.

F10 · price: In connection with the business combination, the reporting person received additional New SAB Biotherapeutics restricted stock units, or RSUs, where each RSU represents a contingent right to receive one share of common stock (the "Earnout RSUs"). The Earnout RSUs will be released upon the same milestones as the Earnout Shares.

F10 · derivative.exercise_date: In connection with the business combination, the reporting person received additional New SAB Biotherapeutics restricted stock units, or RSUs, where each RSU represents a contingent right to receive one share of common stock (the "Earnout RSUs"). The Earnout RSUs will be released upon the same milestones as the Earnout Shares.

F9 · derivative.expiration_date: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, November 1, 2020, with 1/12th vesting every three months following the Vesting Start Date, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date.

SEC source: 0001493152-21-026382 · ownership.xml · derivative · entry 20

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 23,264

Underlying: Common Stock · 23,264 shares

Expires 2030-04-27

F6 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F7 · price: The option is fully vested.

F6 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F7 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026382 · ownership.xml · derivative · entry 19

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 116,321

Underlying: Common Stock · 116,321 shares

Expires 2025-12-15

F6 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F7 · price: The option is fully vested.

F6 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F7 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026382 · ownership.xml · derivative · entry 18

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 162,850

Underlying: Common Stock · 162,850 shares

Expires 2024-12-12

F6 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F7 · price: The option is fully vested.

F6 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F7 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026382 · ownership.xml · derivative · entry 17

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 162,850

Underlying: Common Stock · 162,850 shares

Expires 2024-12-12

F6 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F7 · price: The option is fully vested.

F6 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F7 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026382 · ownership.xml · derivative · entry 16

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 2,009,697

Underlying: Common Stock · 2,009,697 shares

Expires not disclosed

F4 · derivative.exercise_price: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

F5 · derivative.exercise_price: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period.

F4 · price: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

F5 · price: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period.

F4 · derivative.exercise_date: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

F5 · derivative.exercise_date: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period.

F4 · derivative.expiration_date: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

SEC source: 0001493152-21-026382 · ownership.xml · derivative · entry 15

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,777

Underlying: Common Stock · 47,777 shares

Expires not disclosed

F10 · derivative.exercise_price: In connection with the business combination, the reporting person received additional New SAB Biotherapeutics restricted stock units, or RSUs, where each RSU represents a contingent right to receive one share of common stock (the "Earnout RSUs"). The Earnout RSUs will be released upon the same milestones as the Earnout Shares.

F10 · price: In connection with the business combination, the reporting person received additional New SAB Biotherapeutics restricted stock units, or RSUs, where each RSU represents a contingent right to receive one share of common stock (the "Earnout RSUs"). The Earnout RSUs will be released upon the same milestones as the Earnout Shares.

F10 · derivative.exercise_date: In connection with the business combination, the reporting person received additional New SAB Biotherapeutics restricted stock units, or RSUs, where each RSU represents a contingent right to receive one share of common stock (the "Earnout RSUs"). The Earnout RSUs will be released upon the same milestones as the Earnout Shares.

F9 · derivative.expiration_date: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, November 1, 2020, with 1/12th vesting every three months following the Vesting Start Date, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date.

SEC source: 0001493152-21-026382 · ownership.xml · derivative · entry 14

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 69,793

Underlying: Common Stock · 69,793 shares

Expires 2031-01-01

F6 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F9 · price: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, November 1, 2020, with 1/12th vesting every three months following the Vesting Start Date, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date.

F6 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F9 · derivative.exercise_date: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, November 1, 2020, with 1/12th vesting every three months following the Vesting Start Date, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date.

SEC source: 0001493152-21-026382 · ownership.xml · derivative · entry 13

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,264

Underlying: Common Stock · 23,264 shares

Expires 2029-05-03

F6 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F8 · price: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, May 3, 2019, with 1/12th vesting every three months following the Vesting Start Date, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date.

F6 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F8 · derivative.exercise_date: The option shall vest and become exercisable over a period of 36 months from the Vesting Start Date, May 3, 2019, with 1/12th vesting every three months following the Vesting Start Date, such that the option will be fully vested 36 months from the Vesting Start Date, subject to the reporting person's continuous service with the Issuer on each such date.

SEC source: 0001493152-21-026382 · ownership.xml · derivative · entry 12

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,632

Underlying: Common Stock · 11,632 shares

Expires 2028-07-01

F6 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F7 · price: The option is fully vested.

F6 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F7 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026382 · ownership.xml · derivative · entry 11

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,632

Underlying: Common Stock · 11,632 shares

Expires 2025-12-15

F6 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F7 · price: The option is fully vested.

F6 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F7 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026382 · ownership.xml · derivative · entry 10

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,896

Underlying: Common Stock · 34,896 shares

Expires 2025-07-01

F6 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F7 · price: The option is fully vested.

F6 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F7 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026382 · ownership.xml · derivative · entry 9

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,632

Underlying: Common Stock · 11,632 shares

Expires 2024-12-12

F6 · price: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F7 · price: The option is fully vested.

F6 · derivative.exercise_date: Pursuant to the Business Combination Agreement, each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of $10.10.

F7 · derivative.exercise_date: The option is fully vested.

SEC source: 0001493152-21-026382 · ownership.xml · derivative · entry 8

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,039,938

Underlying: Common Stock · 2,039,938 shares

Expires not disclosed

F4 · derivative.exercise_price: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

F5 · derivative.exercise_price: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period.

F4 · price: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

F5 · price: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period.

F4 · derivative.exercise_date: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

F5 · derivative.exercise_date: 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds $30.00 during at least 20 trading days within a 30-day trading period.

F4 · derivative.expiration_date: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

SEC source: 0001493152-21-026382 · ownership.xml · nonDerivative · entry 7

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 4,974,497

F1 · price: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each share of Old SAB Biotherapeutics issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").

SEC source: 0001493152-21-026382 · ownership.xml · nonDerivative · entry 1

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,049,351

F1 · price: Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each share of Old SAB Biotherapeutics issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a number of shares of the Issuer's common stock based on a conversion rate of $10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics" or "Issuer").

SEC source: 0001493152-21-026382 · ownership.xml · nonDerivative · entry 6

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 5,092

F2 · date: This transaction occurred prior to the business combination. The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination.

SEC source: 0001493152-21-026382 · ownership.xml · nonDerivative · entry 5

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 20,800

F2 · date: This transaction occurred prior to the business combination. The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination.

SEC source: 0001493152-21-026382 · ownership.xml · nonDerivative · entry 3

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Christensen Investments, LLC

Disclosed balance after: 25,000

F2 · date: This transaction occurred prior to the business combination. The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination.

F3 · ownership.direct: The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F4 · ownership.direct: Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

SEC source: 0001493152-21-026382 · ownership.xml · nonDerivative · entry 2

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

F2 · date: This transaction occurred prior to the business combination. The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination.

SEC source: 0001493152-21-026382 · ownership.xml · nonDerivative · entry 4

HAMILTON CHRISTINE E · CIK 0001216114 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 2,695

F2 · date: This transaction occurred prior to the business combination. The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination.

SEC source: 0001409171-21-000061 · wf-form4_162318917936784.xml · nonDerivative · entry 1

HAMILTON CHRISTINE E · CIK 0001216114 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,549

SEC source: 0001409171-20-000050 · wf-form4_159173419450012.xml · nonDerivative · entry 1

HAMILTON CHRISTINE E · CIK 0001216114 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,403

SEC source: 0001409171-19-000035 · wf-form4_155992157453129.xml · nonDerivative · entry 1

HAMILTON CHRISTINE E · CIK 0001216114 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,300

SEC source: 0001409171-18-000053 · wf-form4_152849007444427.xml · nonDerivative · entry 1

HAMILTON CHRISTINE E · CIK 0001216114 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,939

SEC source: 0001409171-18-000011 · wf-form4_152026718257038.xml · nonDerivative · entry 1

HAMILTON CHRISTINE E · CIK 0001216114 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 902